As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) ...

Researchers identified finerenone as a potential treatment for POI. Preclinical findings show the drug stimulates follicle ...

Scientists find finerenone may stimulate ovarian follicles and help restore fertility in women with POI, offering a potential ...

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. ("Faeth"), a clinical-stage biotechnology company developing multi-node therapies that target ...

Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — Hong Kong, Shanghai & Florham Park, NJ ...

Premature ovarian insufficiency (POI) affects 1–3% of women and has limited treatment options. Researchers report that ...

Hong Kong, Shanghai Friday, March 6, 2026, 10:00 Hrs [IST] ...

TD Cowen 46th Annual Health Care Conference March 4, 2026 10:30 AM ESTCompany ParticipantsBrian Sullivan - Co-Founder, Chairman ...

Premature ovarian insufficiency (POI) is a clinically significant cause of infertility that affects between 1 to 3% of women of childbearing age ...

The portfolio meaningfully outperformed the MSCI EAFE Small Cap Growth Index but modestly lagged the blend MSCI ACWI ex USA SMID Index. Read more here.